NCT05034887 2026-04-08Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction AdenocarcinomaNational Cancer Center Hospital EastPhase 2 Active not recruiting64 enrolled
NCT05480384 2026-04-01Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal JunctionBrown UniversityPhase 2 Active not recruiting1 enrolled
NCT05633979 2026-01-20Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast CancerM.D. Anderson Cancer CenterPhase 1 Active not recruiting17 enrolled